DelveInsight’s “Irritable Bowel Syndrome (IBS) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Irritable Bowel Syndrome (IBS), historical and forecasted epidemiology as well as the Irritable Bowel Syndrome (IBS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Irritable Bowel Syndrome (IBS) market report provides current treatment practices, emerging drugs, Irritable Bowel Syndrome (IBS) market share of the individual therapies, current and forecasted Irritable Bowel Syndrome (IBS) market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Irritable Bowel Syndrome (IBS) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Irritable Bowel Syndrome (IBS) market.
Key benefits of the Irritable Bowel Syndrome Market report:
The report covers the descriptive overview of Irritable Bowel Syndrome (IBS), explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
Comprehensive insight has been provided into the Irritable Bowel Syndrome (IBS) epidemiology and treatment in the 7MM
Additionally, an all-inclusive account of both the current and emerging therapies for Irritable Bowel Syndrome (IBS) is provided, along with the assessment of new therapies which will have an impact on the current treatment landscape
A detailed review of the Irritable Bowel Syndrome (IBS) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
The report provides an edge while developing business strategies by understanding trends shaping and driving the global Irritable Bowel Syndrome (IBS) market
Got queries? Click here to know more about the Irritable Bowel Syndrome Market Landscape
Irritable Bowel Syndrome Overview
Irritable bowel syndrome (IBS) is one of the most commonly diagnosed gastrointestinal diseases. IBS, in the absence of any other causative disease, is defined as the presence of abdominal pain or discomfort with altered bowel habits. The etiology of Irritable bowel syndrome (IBS) or IBS is broad and not clearly understood. However, the pathophysiology of IBS is broad and includes abnormalities involving motility, visceral sensation, brain-gut interaction, and psychosocial distress.
IBS typically consists of abdominal pain or discomfort, altered bowel habits along with either constipation, diarrhea or both. Other complaints in patients with IBS include bloating, distention, symptoms brought on by food intake, and a change in pain location, and stool pattern with time. IBS has a good prognosis, and the diagnosis is unlikely to change on follow-up. Diagnosis of IBS has evolved since its first discovery, and today the Rome IV diagnostic criteria (The Rome IV consensus is a robust standard for a clinical and research approach to functional gastrointestinal disorders) is used to diagnose IBS.
Irritable Bowel Syndrome Epidemiological Insights:
Irritable bowel syndrome (IBS) can be a very disabling syndrome for patients, and it has been shown to be a very common reason for seeking medical attention. Nearly 12% of patients seek medical care in primary care practices for IBS-related complaints. Studies have demonstrated that the prevalence of IBS ranges between 10-15%. However, the majority of these patients do not seek medical care.
In the United States, IBS symptoms are 1.5 to 2 times more prevalent among women than men. Moreover, women are more likely to report abdominal pain and constipation, whereas men are more likely to report diarrhea.IBS can be broken down into more specific diagnoses, which include IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with mixed bowel patterns (IBS-M). The prevalence of these three diagnoses differs in the United States versus Europe. In the United States, there is an equal distribution of these diagnoses, whereas in Europe IBS-C or IBS-M can be more prevalent.The prevalence of IBS decreases with age, suggesting that symptoms remit over time.
Irritable Bowel Syndrome Epidemiological Segmentation
Irritable Bowel Syndrome is prevalent population
Irritable Bowel Syndrome diagnosed with prevalent cases
Irritable Bowel Syndrome sub type-specific, prevalent cases
Irritable Bowel Syndrome gender specific prevalent cases
Irritable Bowel Syndrome age-specific prevalent cases
Irritable Bowel Syndrome Market Outlook
The Irritable Bowel Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Irritable Bowel Syndrome market trends by analyzing the impact of current Irritable Bowel Syndrome therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the Irritable Bowel Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Irritable Bowel Syndrome market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Irritable Bowel Syndrome market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Irritable Bowel Syndrome Market Landscape
Irritable Bowel Syndrome Key Companies
OrphoMed, Inc
D pharma
And many others
Irritable Bowel Syndrome Key Therapies
ORP-101
Blautix
Table of Contents
Key Insights
Report Introduction
Executive Summary of Irritable Bowel Syndrome Market
Disease Background and Overview
Epidemiology and patient population
The United States
EU 5
Irritable Bowel Syndrome Market Emerging Therapies
Market Access and Reimbursement of Therapies
Appendix
Irritable Bowel Syndrome Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
Click here to read more about the Irritable Bowel Syndrome Market
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services